{"id":6740,"date":"2024-10-18T11:46:16","date_gmt":"2024-10-18T11:46:16","guid":{"rendered":"https:\/\/ibsal.es\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\/"},"modified":"2025-03-10T18:57:35","modified_gmt":"2025-03-10T18:57:35","slug":"new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer","status":"publish","type":"post","link":"https:\/\/ibsal.es\/en\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\/","title":{"rendered":"New study reveals that the PADI3 enzyme contributes to resistance to neratinib treatment in HER2-positive breast cancer"},"content":{"rendered":"\n<p>A recent study carried out by researchers belonging to the Cancer Research Center (CSIC-University of Salamanca), IBSAL and CIBERONC and published in the open access journal <em>Oncogenesis<\/em> has revealed a new mechanism that could explain why some patients with HER2-positive breast cancer develop resistance to treatment with neratinib, a HER2 inhibitor drug. The presence of high amounts of HER2 protein is detected in approximately 20% of breast tumor cases, allowing treatment with targeted therapies such as neratinib. However, despite the initial benefits, some patients eventually develop resistance to the drug, which limits its long-term effectiveness.  <\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p>The research team has discovered that the enzyme peptidylarginine deiminase 3 (PADI3), previously little studied in the context of breast cancer, plays a crucial role in this resistance process. Using cellular models, the researchers observed that HER2-positive human cancer cells that had become resistant to neratinib exhibited elevated levels of PADI3. Surprisingly, by reducing or inhibiting PADI3 activity, the cells became sensitive to treatment again.  <\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<figure class=\"wp-block-image aligncenter size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"522\" height=\"522\" src=\"https:\/\/ibsal.es\/wp-content\/uploads\/2024\/10\/asaas.png\" alt=\"\" class=\"wp-image-3234\" srcset=\"https:\/\/ibsal.es\/wp-content\/uploads\/2024\/10\/asaas.png 522w, https:\/\/ibsal.es\/wp-content\/uploads\/2024\/10\/asaas-300x300.png 300w, https:\/\/ibsal.es\/wp-content\/uploads\/2024\/10\/asaas-150x150.png 150w\" sizes=\"(max-width: 522px) 100vw, 522px\" \/><\/figure>\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>Image of human breast cancer cells, stained to identify HER2, shown in red. The staining marks the cell surface, which is where this protein is found. <\/p>\n<\/blockquote>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p><em>&#8220;This discovery defines one of the causes of resistance to neratinib, and will allow us to better understand why cells become refractory to that treatment<\/em>,&#8221; explained Atanasio Pandiella, director of the study. The results suggest that PADI3 inhibitors could be used as a therapeutic option to restore the efficacy of neratinib in patients who have developed resistance. <\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p>The research also showed that when high levels of PADI3 were introduced into cancer cells that originally responded to treatment, they developed resistance to neratinib. This confirms the direct link between PADI3 and the ability of HER2-positive breast cancer to escape treatment with neratinib. &#8220;<em>It is even possible that PADI3 may be involved in resistance to other types of drugs<\/em>,&#8221; Pandiella adds.<\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p>This advance not only provides a better understanding of the mechanisms of resistance in HER2-positive breast cancer, but also suggests that PADI3 could become a marker for predicting which patients might benefit from new treatment combinations.<\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p>This work has been developed thanks to public funding provided by the Ministry of Science, Innovation and Universities, the Junta de Castilla y Le\u00f3n, the CIBERONC consortium, and by donations from several private associations such as ALMOM, ACMUMA, UCCTA, and the CRIS Foundation.<\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p>Link to article: <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC11297914\/\">Peptidylarginine deiminase 3 modulates response to neratinib in HER2 positive breast cancer &#8211; PMC (nih.gov)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A recent study carried out by researchers belonging to the Cancer Research Center (CSIC-University of Salamanca), IBSAL and CIBERONC and published in the open access journal Oncogenesis has revealed a [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":6304,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_tribe_ticket_capacity":"0","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":""},"categories":[238],"tags":[242],"class_list":["post-6740","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-cancer-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.12 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>New study reveals that the PADI3 enzyme contributes to resistance to neratinib treatment in HER2-positive breast cancer | IBSAL<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibsal.es\/en\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New study reveals that the PADI3 enzyme contributes to resistance to neratinib treatment in HER2-positive breast cancer\" \/>\n<meta property=\"og:description\" content=\"A recent study carried out by researchers belonging to the Cancer Research Center (CSIC-University of Salamanca), IBSAL and CIBERONC and published in the open access journal Oncogenesis has revealed a [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibsal.es\/en\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"IBSAL\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-18T11:46:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-10T18:57:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ibsal.es\/wp-content\/uploads\/2024\/10\/Lab15-1-1-e1730375386792.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2000\" \/>\n\t<meta property=\"og:image:height\" content=\"1126\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sergi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sergi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\\\/\"},\"author\":{\"name\":\"Sergi\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/#\\\/schema\\\/person\\\/34ba5672452d5f86b117e6cb49a6bb97\"},\"headline\":\"New study reveals that the PADI3 enzyme contributes to resistance to neratinib treatment in HER2-positive breast cancer\",\"datePublished\":\"2024-10-18T11:46:16+00:00\",\"dateModified\":\"2025-03-10T18:57:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\\\/\"},\"wordCount\":423,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ibsal.es\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/Lab15-1-1-e1730375386792.jpg\",\"keywords\":[\"Cancer\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/ibsal.es\\\/en\\\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\\\/\",\"url\":\"https:\\\/\\\/ibsal.es\\\/en\\\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\\\/\",\"name\":\"New study reveals that the PADI3 enzyme contributes to resistance to neratinib treatment in HER2-positive breast cancer | IBSAL\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ibsal.es\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/Lab15-1-1-e1730375386792.jpg\",\"datePublished\":\"2024-10-18T11:46:16+00:00\",\"dateModified\":\"2025-03-10T18:57:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/#\\\/schema\\\/person\\\/34ba5672452d5f86b117e6cb49a6bb97\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibsal.es\\\/en\\\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ibsal.es\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/Lab15-1-1-e1730375386792.jpg\",\"contentUrl\":\"https:\\\/\\\/ibsal.es\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/Lab15-1-1-e1730375386792.jpg\",\"width\":2000,\"height\":1126},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibsal.es\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New study reveals that the PADI3 enzyme contributes to resistance to neratinib treatment in HER2-positive breast cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/ibsal.es\\\/en\\\/\",\"name\":\"IBSAL\",\"description\":\"Benchmarks in translational research in biomedicine in Castilla y Le\u00f3n\",\"alternateName\":\"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibsal.es\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/#\\\/schema\\\/person\\\/34ba5672452d5f86b117e6cb49a6bb97\",\"name\":\"Sergi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/528ac3b73275e0b7aaacef0c293ace2a4935f7e6f58f8b31465b2faf9ae5ed56?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/528ac3b73275e0b7aaacef0c293ace2a4935f7e6f58f8b31465b2faf9ae5ed56?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/528ac3b73275e0b7aaacef0c293ace2a4935f7e6f58f8b31465b2faf9ae5ed56?s=96&d=mm&r=g\",\"caption\":\"Sergi\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"New study reveals that the PADI3 enzyme contributes to resistance to neratinib treatment in HER2-positive breast cancer | IBSAL","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibsal.es\/en\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\/","og_locale":"en_US","og_type":"article","og_title":"New study reveals that the PADI3 enzyme contributes to resistance to neratinib treatment in HER2-positive breast cancer","og_description":"A recent study carried out by researchers belonging to the Cancer Research Center (CSIC-University of Salamanca), IBSAL and CIBERONC and published in the open access journal Oncogenesis has revealed a [&hellip;]","og_url":"https:\/\/ibsal.es\/en\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\/","og_site_name":"IBSAL","article_published_time":"2024-10-18T11:46:16+00:00","article_modified_time":"2025-03-10T18:57:35+00:00","og_image":[{"width":2000,"height":1126,"url":"https:\/\/ibsal.es\/wp-content\/uploads\/2024\/10\/Lab15-1-1-e1730375386792.jpg","type":"image\/jpeg"}],"author":"Sergi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Sergi","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ibsal.es\/en\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\/#article","isPartOf":{"@id":"https:\/\/ibsal.es\/en\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\/"},"author":{"name":"Sergi","@id":"https:\/\/ibsal.es\/en\/#\/schema\/person\/34ba5672452d5f86b117e6cb49a6bb97"},"headline":"New study reveals that the PADI3 enzyme contributes to resistance to neratinib treatment in HER2-positive breast cancer","datePublished":"2024-10-18T11:46:16+00:00","dateModified":"2025-03-10T18:57:35+00:00","mainEntityOfPage":{"@id":"https:\/\/ibsal.es\/en\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\/"},"wordCount":423,"commentCount":0,"image":{"@id":"https:\/\/ibsal.es\/en\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/ibsal.es\/wp-content\/uploads\/2024\/10\/Lab15-1-1-e1730375386792.jpg","keywords":["Cancer"],"articleSection":["News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ibsal.es\/en\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ibsal.es\/en\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\/","url":"https:\/\/ibsal.es\/en\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\/","name":"New study reveals that the PADI3 enzyme contributes to resistance to neratinib treatment in HER2-positive breast cancer | IBSAL","isPartOf":{"@id":"https:\/\/ibsal.es\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ibsal.es\/en\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\/#primaryimage"},"image":{"@id":"https:\/\/ibsal.es\/en\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/ibsal.es\/wp-content\/uploads\/2024\/10\/Lab15-1-1-e1730375386792.jpg","datePublished":"2024-10-18T11:46:16+00:00","dateModified":"2025-03-10T18:57:35+00:00","author":{"@id":"https:\/\/ibsal.es\/en\/#\/schema\/person\/34ba5672452d5f86b117e6cb49a6bb97"},"breadcrumb":{"@id":"https:\/\/ibsal.es\/en\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibsal.es\/en\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ibsal.es\/en\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\/#primaryimage","url":"https:\/\/ibsal.es\/wp-content\/uploads\/2024\/10\/Lab15-1-1-e1730375386792.jpg","contentUrl":"https:\/\/ibsal.es\/wp-content\/uploads\/2024\/10\/Lab15-1-1-e1730375386792.jpg","width":2000,"height":1126},{"@type":"BreadcrumbList","@id":"https:\/\/ibsal.es\/en\/new-study-reveals-that-the-padi3-enzyme-contributes-to-resistance-to-neratinib-treatment-in-her2-positive-breast-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibsal.es\/en\/"},{"@type":"ListItem","position":2,"name":"New study reveals that the PADI3 enzyme contributes to resistance to neratinib treatment in HER2-positive breast cancer"}]},{"@type":"WebSite","@id":"https:\/\/ibsal.es\/en\/#website","url":"https:\/\/ibsal.es\/en\/","name":"IBSAL","description":"Benchmarks in translational research in biomedicine in Castilla y Le\u00f3n","alternateName":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibsal.es\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ibsal.es\/en\/#\/schema\/person\/34ba5672452d5f86b117e6cb49a6bb97","name":"Sergi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/528ac3b73275e0b7aaacef0c293ace2a4935f7e6f58f8b31465b2faf9ae5ed56?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/528ac3b73275e0b7aaacef0c293ace2a4935f7e6f58f8b31465b2faf9ae5ed56?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/528ac3b73275e0b7aaacef0c293ace2a4935f7e6f58f8b31465b2faf9ae5ed56?s=96&d=mm&r=g","caption":"Sergi"}}]}},"_links":{"self":[{"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/posts\/6740","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/comments?post=6740"}],"version-history":[{"count":0,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/posts\/6740\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/media\/6304"}],"wp:attachment":[{"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/media?parent=6740"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/categories?post=6740"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/tags?post=6740"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}